ABO-102 results presented at WORLDSymposium for Lysosomal Diseases show significant time- and dose-dependent reduction of underlying Disease pathology, including decreased CSF and urine GAGs (HS fragments) and diminished liver volumes Evidence of cognitive benefit at six months post treatment in Cohort 2 and at one year in Cohort 1 Company receives FDA allowance to lower […]